Mycenax Biotech Inc. (4726) highlighted its operational performance, capacity strategy, technology progress, and strategic outlook at an investor conference hosted by MasterLink Securities Corp on June 30. CEO and President Pei-Jiun Chen stated that Mycenax’s strategic transformation in 2019 to a specialized biopharmaceutical CDMO (Contract Development and Manufacturing Organization) has begun to yield significant results. Starting in the second half of 2025, Mycenax will begin commercial production for two internationally approved biologics—marking a significant step forward in its global strategy. One of the products, transferred from a Japanese customer, received marketing approval in May and is now stably marketed in Japan. Mycenax has signed a long-term manufacturing agreement to support its continued supply. The second product, a biosimilar to Eylea developed by a South Korean customer SCD, has reached the commercial production stage with Mycenax as its manufacturing partner. Global launches are expected to roll out in stages. These products are expected to become key contributors to Mycenax’s long-term revenue growth.
In a further move to strengthen its international presence, Mycenax is partnering with three major Japanese companies—Alfresa (one of Japan’s top three pharma distributors), Kidswell (a leading biosimilar developer), and Chiome (a biotech new drug R&D company)—to establish a biopharmaceutical manufacturing site in Japan. The project received funding support in May from Japan’s Ministry of Health, Labour and Welfare. The new GMP facility will support both drug substance (DS) and drug product (DP) manufacturing. This collaboration highlights the recognition Mycenax has earned in Japan and strengthens our strategic positioning in the global CDMO market. It’s also an important step in diversifying our operations and mitigating geopolitical risks.
CEO and President Pei-Jiun Chen stated that with a strong technical foundation and successful inspections from major global regulatory authorities, combined with technical strengths, Mycenax has been invited to participate in establish a biopharmaceutical manufacturing site in Japan. Looking ahead, Mycenax continues to build trust across international markets, remaining focused on innovation, quality, and global expansion as it aims to offer one-stop services for the biopharmaceutical industry, becoming a globally recognized Bio-CDMO.
Mycenax Biotech Inc. (4726) highlighted its operational performance, capacity strategy, technology progress, and strategic outlook at an investor conference hosted by MasterLink Securities Corp on June 30. CEO and President Pei-Jiun Chen stated that Mycenax’s strategic transformation in 2019 to a specialized biopharmaceutical CDMO (Contract Development and Manufacturing Organization) has begun to yield significant results. Starting in the second half of 2025, Mycenax will begin commercial production for two internationally approved biologics—marking a significant step forward in its global strategy. One of the products, transferred from a Japanese customer, received marketing approval in May and is now stably marketed in Japan. Mycenax has signed a long-term manufacturing agreement to support its continued supply. The second product, a biosimilar to Eylea developed by a South Korean customer SCD, has reached the commercial production stage with Mycenax as its manufacturing partner. Global launches are expected to roll out in stages. These products are expected to become key contributors to Mycenax’s long-term revenue growth.
In a further move to strengthen its international presence, Mycenax is partnering with three major Japanese companies—Alfresa (one of Japan’s top three pharma distributors), Kidswell (a leading biosimilar developer), and Chiome (a biotech new drug R&D company)—to establish a biopharmaceutical manufacturing site in Japan. The project received funding support in May from Japan’s Ministry of Health, Labour and Welfare. The new GMP facility will support both drug substance (DS) and drug product (DP) manufacturing. This collaboration highlights the recognition Mycenax has earned in Japan and strengthens our strategic positioning in the global CDMO market. It’s also an important step in diversifying our operations and mitigating geopolitical risks.
CEO and President Pei-Jiun Chen stated that with a strong technical foundation and successful inspections from major global regulatory authorities, combined with technical strengths, Mycenax has been invited to participate in establish a biopharmaceutical manufacturing site in Japan. Looking ahead, Mycenax continues to build trust across international markets, remaining focused on innovation, quality, and global expansion as it aims to offer one-stop services for the biopharmaceutical industry, becoming a globally recognized Bio-CDMO.